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Introduction  
Psoriasis is a common skin disease characterized by reddish patches 
covered with silvery scales. It can occur in any part of the body. It is a 
noncontagious autoimmune disease with remissions and exacerbations being 
characteristic of this disease.  
It is associated with extra cutaneous manifestations such as joint 
involvement, eye involvement and an increased risk of coronary artery 
disease. 
Joint involvement can be in the form or peripheral arthritis, spondylitis 
and enthesitis. It can range from monoarticular involvement to severe 
destructive form of arthritis. The occurrence is generally preceded by skin 
lesions, but there is no correlation between the severity of the skin lesions and 
the occurrence of joint disease.   
The occurrence of ocular inflammation is psoriasis is known for many 
years but not very well investigated. It has very subtle presentation and any 
times is diagnosed after irreversible damage has occurred to the ocular tissue. 
This delay in presentation maybe due to lack of awareness among patients, 
less no. of signs and symptoms and delay in referrals. 
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The various manifestations maybe due to the disease per se or as a 
result of the treatment given for the disease. The various findings range from 
Blepharitis, Conjunctivitis, dry eye, Episcleritis, Marginal keratitis and the 
sight threatening uveitis.  
Psoriasis is also associated with a significant amount of social 
stigmatization, absenteeism from work, emotional stress and physical pain. (1) 
Thorough ocular evaluation and treatment is essential for a wholesome 
treatment of the psoriasis patients. 
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Review of literature 
Studies regarding the ocular manifestations of psoriasis date back to 
1959 when Wright described the occurrence of lid, conjunctiva and corneal 
involvement in patients with psoriatic arthritis. 
In 1970 Peter Eustace and Dermot Pierse reported two cases of 
marginal keratitis associated with psoriasis. 
Psoriatic eye manifestations - a review article published in psoriasis 
forum vol3 in fall 2011 highlights the various ocular manifestations including 
Blepharitis, Conjunctivitis, Episcleritis and Uveitis. 
A population based study of ocular findings in psoriasis patients was 
done in the Department of Dermatology, Yozgat State Hospital, Yozgat, 
Turkey. They analyzed 100 patients and compared them to 100 age matched 
controls. They concluded that the ocular findings in psoriasis patients were 
higher compared to the age matched control and stressed on the need for early 
referral to an ophthalmologist. 
Another population based study was done to assess the ocular findings 
in patients with psoriatic arthritis in Brazilian population and published in the 
year 2012.This cross sectional study included 40 psoriatic arthritis patients 
and 40 age matched controls. They found keratoconjunctivitis sicca to be the 
most common associated ocular finding. (2) 
13 
 
A study of ocular findings in Singaporean Asian population was done 
in 2007. This study included 100 patients with plaque type of psoriasis. They 
concluded that the Lattice System Physician's Global Assessment (LS-PGA) 
score, a scoring system used to grade the severity of the disease could act as a 
parameter for referring the patients for ophthalmic evaluation. They found 
that a score of more than 5 should prompt an ophthalmological examination 
for the patient. 
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RELEVANT NANTOMY  
Eyelids 
Anatomy  
The upper eyelid extends from eyebrows downwards to end in a free 
margin and lower lid ends by merging with the cheek. 
Eyelid margins- it is 2mm wide. Each margin is divided into 2 parts by 
the lacrimal papilla. Lacrimal portion is the medial part of eyelid margin 
extending from the puntum medially to medial canthus. It is rounded and 
devoid of lashes and glands. Ciliary part is the lateral part. It has a rounded 
anterior border and a sharp posterior border and an inter marginal strip 
between the 2 borders. The grey line divides this strip into an anterior part 
which bears the eyelashes and posterior part which contains opening of 
Meibomian glands. 
Eyelashes are arranged in 2-3 rows, 100-150 in number in the upper lid 
and 50-75 in the lower lid. The lash follicles pass obliquely in the lid and are 
embedded in the fibrous tissue that binds the ciliary margin and the tarsus. 
The gland of Zeis and Moll empty into the base of the hair follicle. It is 
surrounded by a rich plexus of nerves and vessel. 
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The various layers of the eye lid are skin, subcutaneous areolar tissue, 
layer of striated muscle consisting of orbicularis oculi and the Levator 
Palpebrae Superioris. The submuscular areolar tissue consisting of the nerves 
and vessels of the lid. Fibrous layer consisting of the Tarsal plate, layer of non 
striated muscle- Mullers muscle and the last layer is the conjunctiva. 
The various gland of the eyelid are: MEIBOMIAN Gland these are 
modified sebaceous glands present in posterior part of stroma of tarsal plate. 
The functions of the oily secretions are  
1. Prevents overflow of tears across the lid margin 
2. Prevents evaporation of tears 
3. Allows smooth movement of the eyelids 
4. Ensures air tight closure of the eye lids. 
ZEIS Gland it is a modified sebaceous gland its secretions prevent the eye 
lash from becoming brittle and contribute to the oily layer of the tear film. 
MOLLS Glands these are modified sweat glands. 
ACCESSORY LACRIMAL GLANDS OF KRAUSE AND WOLFRING they 
are present in the superior border of tarsus in upperlid and inferior border of 
tarsus in lower lid. They contribute to the bulk of the aqueous portion of the 
tear film. 
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BLOOD SUPPLY 
Arteries- medial and lateral palpebral arteries which are branches of 
dorsal nasal and lacrimal arteries. The superior and inferior palpebral arteries 
anastomose with the lateral palpebral artery 2-3mm away from the lid margin 
forming the marginal arterial arcade. In the upper lid another anastomoses 
exists called the peripheral arterial arcade formed by the superior branch of 
medial palpebral artery. 
Veins- two sets of venous plexus drain the lids.  pretarsal venous 
plexus it drains into angular vein on the medial side and the temporal and 
lacrimal vein on the lateral side. post tarsal plexus drains into the ophthalmic 
veins  
Nerve supply motor- facial nerve, sensory supply- upper lid supra 
orbital, supra trochlear, infratrochlear and lacrimal, lower lid infra orbital, 
infratrochlear, lacrimal. Branches of first and second part of trigeminal 
nerves. Sympathetic nerves supply the Mullers muscle, the vessels and the 
glands. 
17 
 
 
 
 
 Tear film 
Tear film consists of 3 layers 
Lipid layer this is the outer most oily layer derived from the secretions 
of Meibomian, Zeiss and Moll glands. Chemically this layer consists of low 
polarity lipids such as wax and cholesterol esters. The thickness of this layer 
is 0.1micron. 
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Aqueous layer this is the middle layer. It is secreted by the lacrima 
gland and the accessory glands of Krausse and Wolfring. The thickness is 
10microns. This layer contains ions of inorganic salts, glucose, urea, proteins, 
glycoproteins, lysozymes, lactoferrin, tear specific prealbumin and 
immunoglobulin A. 
Mucus layer this layer is secreted by conjunctival goblet cells, crypts of 
Henle and glands of Manz. It is essential for the stability of the tear film. It 
gets absorbed on the cell membrane of epithelial cells and anchored by their 
microvilli forming a new hydrophilic surface on which aqueous and lipid 
layers spread spontaneously.it has a thickness of 0.02-30 microns 
The average thickness of the tear film varies from 4to 8 microns. Volume of 
tear film is 4-13 microliters. Normal tear secretion is 1.2µl with total 24 hrs 
secretion of 10cubic ml. Refractive index of tear film is 1.357. pH of the tears 
is nearly 7.4 equal to plasma pH. 
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Conjunctiva   
Conjunctiva is a translucent mucous membrane which lines the back of 
the eyelids and the front of the eye ball. It extends from the lids to the limbus 
and encloses the conjunctival sac.  
The various parts of the conjunctiva are 
 Palpebral conjunctiva consisting of marginal, tarsal and orbital part. 
 Bulbar conjunctiva consisting of scleral and limbal part. 
 Superior inferior medial and lateral fornixes. 
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Histologically it consists of  
 Epithelial layer- Non keratinised stratified squamous epithelium it is 
present in different no. of layers in the different parts of the 
conjunctiva. Goblet cells these are present in between the epithleal cells 
in all the parts of the conjunctiva . melanocytes are present at the 
limbus, fornix, caruncle and at the site of entry of anterior ciliary 
vessels. Langerhans cells are also present they are the antigen 
presenting cells, help in lymphokines and prostaglandin production. 
 Adenoid layer- also called lymphoid layer. It consists of connective 
tissue with lymphocytes. It is not present at birth and develops after 2-3 
months of life. 
 Fibrous layer –it consists of collagenous and elastic fibres, vessels and 
nerves of the conjunctiva. In the bulbar conjunctiva it blends with the 
Tenons capsule.  
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Glands of the conjunctiva 
 Mucin glands- goblet cells seen in all parts of conjunctiva except 
marginal part and limbus. They are maximum in the nasal part and 
inferior fornix. Mucus is essential for tear film stability and reduction 
in the goblet cell no. can cause dry eye. Henle’s glands-  crypts of 
Henle are folds of the mucous membrane present in the between the 
tarsal and fornix conjunctiva. 
 Accessory lacrimal glands of Krause and Wolfring. 
BLOOD SUPPLY The blood supply of the conjunctiva is derived from 
the  
 Marginal arterial arcade- the perforating branches from the marginal 
arcade pierce the sulcus subtarsalis to reach the conjunctiva. 
 Peripheral arterial arcade- perforating branches from this arcade pierce 
the palpebral part to reach the conjunctiva and divide into ascending 
and descending branches. The descending branch supplies the tarsal 
conjunctiva and anastomose with the branches of the marginal arcade at 
the level of sulcus subtarsalis. The ascending branch bends around the 
superior fornix under the bulbar conjunctiva as posterior conjunctival 
artery. 
 Pericorneal plexus is formed 4mm from the limbus by the anastomosis 
between the posterior conjunctival artery and the anterior conjunctiva 
artery which is a branch of the anterior ciliary artery. 
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 Anterior conjunctival artery a branch of anterior ciliary artery is given 
off 4 mm from the limbus. They form a series of arcades parallel to the 
cornea.  
Venous drainage- the veins drain into the venous plexus of the 
lids which drain into superior and inferior ophthalmic veins. 5-6mm of 
circumcorneal zone drains into the anterior ciliary veins.  
Lymphatics – arranged in a superficial and deep layer. From the 
lateral side they drain into the preauricular lymph nodes and from the 
medial side into the submandibular lymph nodes. 
Nerve supply- circumcorneal zone by long ciliary nerve. Rest of 
the conjunctiva- lacrimal, infratrochlear, supra trochlear, supraorbital 
and frontal nerves. 
Uvea  
The uveal tissue is the vascular coat of the eye ball it consists of iris, 
ciliary body and choroid. 
Iris  
It is a circular disc of 12mm diameter and 0.5mm thickness. It has a 3-
4mm central opening- pupil. At the periphery the iris root is attached to the 
middle part of the anterior surface of the ciliary body. The iris divides the 
space between the cornea and lens into anterior and posterior chamber. 
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 Macroscopic appearance  
Anterior surface of the iris- it is divided into pupillary zone and ciliary zone 
by a collarette. 
Ciliary zone has radial streaks, crypts and contraction furrows. 
Pupillary zone is about 1.6mm zone between the collarette and the pupillary 
frill. 
Microscopic structure 
 Anterior limiting layer- it is anterior most condensed form part of 
stroma and it contains melanocytes and fibroblasts. The definitive 
colour of iris is due to this layer. 
 Iris stroma- it forms the main bulk of the iris. It consists of sphincter 
pupillae muscle, dilator pupillae, vessels, nerves, pigment cells , 
lymphocytes, fibroblasts and macrophages. 
o Sphincter pupillae it is a 1mm broad circular band in the 
pupillary part of iris. It is supplied by the parasympathetic fibers. 
o Dilator pupillae it lies in the posterior part of the ciliary zone. It 
is supplied by the cervical sympathetic nerves and dilates the 
pupil. 
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o Vessels the radial vessels of the iris are derived from the circulus 
arteriosus major and are the cause for the radial streaks seen on 
anterior surface of the iris. These vessels are peculiar due to their 
absence of internal elastic lamina and non fenestrated capillary 
endothelium. 
o Pigment cells and melanocytes are present. 
 Anterior epithelial layer it is the anterior continuation of the pigment 
epithelium of retina and ciliary body. This layer is lacking in 
melanocytes. The basal processes of this layer give rise to dilator 
pupillae muscle. 
 Posterior pigment epithelial layer – it is the anterior continuation of the 
non pigmented epithelium of ciliary body, which is the continuation of 
the sensory retina. 
Ciliary Body  
It is a triangular forward extension of the choroid at the ora serrate.  
Macroscopic structure- it is triangular in shape. The outer side of the triangle 
lies against the sclera. The anterior part forms a part of the angle and the 
posterior chamber. The iris is attached to the center of this surface. The inner 
side is divided into anterior 2-2.5mm of pars plicata and posterior smooth pars 
plana. It is 5mm wide temporally and 3mm wide nasally. 
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Microscopic structure- the structures from outwards to inwards are: 
 Supraciliary lamina- it is the continuation of suprachoroidal lamina and 
anteriorly continues as anterior limiting membrane of iris. It is a 
condensed part of stroma and consists of pigmented collagen fibers. 
 Stroma consists of connective tissues , ciliary muscles, vascular 
stroma, nerves and pigment cells. 
o Ciliary muscles- non striated muscles with 3 parts the 
longitudinal fibers, the circular fibers and the radial fibers 
 Longitudinal fibers or meridional fibers- take origin from 
the tendinous fibers from the scleral spur and adjacent 
trabeculae and run posteriorly to get inserted into the 
suprachoroidal lamina beyond the equator. 
 Circular fibers- they run parallel to the limbus and are 
nearest to the lens. 
 Radial fibers- they are oblique fibers which become 
continuous with the circular fibers. The main action of the 
ciliary body muscles is to sclaken the zonules and cause 
accomadation. The longitudinal fibers may help in 
aqueous drainage also.   
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o Vessels the major arterial circle lies in this connective tissue. It 
is formed by the anastomosis of the long posterior ciliary arteries 
and the anterior ciliary artery and supply the iris and the ciliary 
body. 
 Layer of pigmented epithelium- it is the continuation of the RPE and 
continues anteriorly as the anterior pigments epithelium of the iris. 
 Layer of non pigmented epithelium – it the continuation of the 
neurosensory retina and continues anteriorly as the posterior pigmented 
epithelium of the iris. 
 Internal limiting membrane- it is the forward continuation of the 
internal limiting membrane. 
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Choroid  
 
It extends from the optic disc to ora serrate. 
Microscopic structure: from outside inwards the structures are as follows  
 Suprachoroidal lamina-  it is a membrane of condensed collagen 
fibres, melanocytes and fibroblasts. The potential space between 
this membrane and the sclera is called suprachoroidal space 
which contains the long and short posterior ciliary arteries and 
nerves. 
 Stroma of the choroid- it consists of elastic fibres, reticular 
fibres, pigment cells, macrophages , mast cells, plasma cells, 
lymphocytes and vessels. The vessels are arranged in two 
layers. The outer larger layer of Haller’s, the inner medium 
sized vessels Sattlers layer. These terminate as small arterioles 
and connect to the choriocapillaries. The outter most part 
contains the veins. 
 Choriocapillaries – these are fenestrated capillaries. They 
supply the RPE and outer layers of the retina. They are divided 
into non over lapping lobules. 
 Basal lamina or Bruch’s membrane- it’s the inner most layer of 
the choroid and is 2-4µm thick. It consists of the basement 
membrane of the RPE, an inner collagen layer, a middle elastic 
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layer, an outer collagen layer and the basement membrane of the 
choriocapillaris. 
Blood supply is through the Short posterior ciliary arteries. They 
arise as two branches from the ophthalmic artery and divide into 
10-20 branches around the optic nerve and form the circle of zinn- 
Haller and supply the choroid in a segmental manner. 
Venous drainage- this is through the vortex veins. They are 4 in no. 
and situated 6 mm behind the equator of the globe. They are 
present at the superotemporal, inferotemporal, superonasal and 
infero nasal location. At the choroidal end they have an 
ampulliform dilatation. They drain blood from the entire choroid, 
small veins from the retina, small veins from the optic nerve head. 
The two superior vortex veins drain into the superior ophthalmic 
vein either directly or through the muscular or lacrimal tributaries. 
The two inferior veins drain into the inferior ophthalmic veins. 
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Psoriasis	introduction	
	History		
The term psoriasis was first used by Galen. 
Epidemiology  
Prevalence  
Prevalence in different parts of the world is different, world wide 
prevalence is 0.1- 3% of general population. In India the prevalence of 
psoriasis is 0.8%- 5.6% based on clinical and hospital studies.1 
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Age of onset  
There is a bimodal age of onset, first peak at 15-20 years and second 
peak at 55-60yrs. 
Based on the age of onset there are two type 
Type 1- hereditary  
Early onset  <40 years, hereditary, patients have HLA association 
Type 2-sporadic  
Late onset, no family history, no HLA association 
Sex ratio  
There is almost equal frequency of distribution among males and 
females world wide. In Indian studies a slight male preponderance was noted. 
(1)  
Genetic inheritance (2) 
30% of the patients have an affected first degree relative. 
Psoriasis develops in half of the siblings if both parents are affected, 
16% of the siblings if 1 parent is affected and 8% if neither parent is affected.  
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HLA- human leucocyte antigen / histocompatibility lymphocyte antigen 
All animals with WBC’s express a family of cell surface glycoproteins called 
Major Histocompatibility Antigen, in humans its called Human Leucocyte 
Antigen (HLA)  
 
There are 6 different families of HLA 
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Class 1  
It is found on all nucleated cells. It has 3 loci –A, -B, -C 
It consists of 3 alpha chains and 1 beta2 microglobulin glycoprotein which is 
non covalently linked to it. 
There are many polymorphic variations to these loci, 
 eg: 25 alleles for HLA –A, 50 alleles for HLA –B and 10 for HLA-C . 
This HLA class has following functions 
1. Serves as recognition antigen for cytotoxic CD8 Tcells. 
2. They participate in allograft rejection. 
3. They participate in autoimmune diseases. 
Class 2 
This class has 3 loci –DR, -DP, -DQ 
It consists of 2 alpha chains of 35000Da molecular weight and 2 beta chains 
of 28000Da molecular weight non covalently bound to each other. 
There are 100 alleles for –DR 
Class 3 
It consists of components of the complement cascade. 
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Each individual has 1 haplotype from each parent. An APC thus expresses 6 
pairs of HLA. 
The presence of many different HLA alleles within a population 
ensures that the adaptive immunity in at least some individuals in the whole 
group will be able to respond to a wide range of potential pathogens. 
Conversely some individuals may have an increased risk of immunologic 
diseases because of either aberrantly strong immune response to a benign 
pathogen or autoimmune disease arising from inappropriate recognition of 
host peptides as foreign. 
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Presence of certain HLA types have been linked with disease 
occurrence. The inappropriate expression of the antigen coupled with lapse of 
immune surveillance could lead to disease.  The reason for this occurrence 
has been hypothesized as molecular mimicry. Clones of the immune cells can 
escape positive and negative selection process in the thymus. They are then 
activated by exogenous factors and mount a response against the self peptides. 
This hypothesis is present in the context of HLA B27. 
HLA Disease association 
HLA disease association is defined as the statistically increased frequency of 
a HLA haplotype in persons with that disease compared to the frequency in a 
disease free population. 
The ratio of these frequencies is called relative risk. 
HLA association identifies individuals at risk but it is not a diagnostic marker. 
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HLA associations of psoriasis  
S.no.  HLA type  Charecteristics  
1. HLA- B13, -Bw57, -Cw6, -
DR7 
Early onset psoriasis 
2. HLA- A2, -B27 Late onset psoriasis 
3. HLA- Cw6 Exacerbation following streptococcal 
infections 
4. HLA- B13, -B17 Guttate and erythrodermic psoriasis 
5. HLA- Cw6, - B13, B16,B17 Psoriasis with or without arthritis 
6. HLA- B27, -B7, -B38, -B39 Psoriatic arthritis 
7. HLA- B27 Pustular psoriasis, acrodermatitis, 
psoriatic arthritis with spinal 
involvement. 
8. HLA- B38, -B39 Psoriatic arthritis, peripheral arthritis 
9. HLA- DR4 Rheumatoid like psoriatic arthritis 
10. HLA-Aw19, -Bw35 Pustulosis of palms and soles 
11. HLA- B39, -B27, -DQw3 Disease progression in early psoriatic 
arthritis 
12. HLA –B22 Protective for disease progression 
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Pathophysiology of psoriasis 
Psoriasis is characterized by infiltration of the skin with activated T 
cells, these elaborate cytokines and growth factors which stimulate the 
keratinocytes and cause hyper proliferation. 
Antigen triggers cause T cell proliferation. There is a dysregulation in T cells 
leading to increased proliferation of Th1 Th 17 cells and antigen presenting 
cells. These release cytokines and other growth mediators causing hyper 
proliferation of keratinocytes which is seen clinically as scaly lesions. There 
is increased production of vascular growth factors seen as Auspitz sign 
clinically. 
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Triggering and modifying factors of psoriasis 
Psoriasis has a chronic relapsing and remitting course with certain triggers. 
The factors which trigger and modify psoriasis are 
1. Local injury to the skin can cause new lesion formation in the site of 
injury to the papillary dermis. This is called as Koebners phenomenon. 
2. Seasonal variations- worsening in winter seasons. 
3. Pregnancy- pregnancy generally causes remission. There maybe an 
exacerbation in the post partum period. 
4. Emotional stress- upto 60% patients have exacerbation following 
stress. 
5. Infections – many infections can cause exacerbations. URI especially 
with streptococcal species flares up psoriasis or precipitates Guttate 
psoriasis. Similarly HIV may exacerbate the disease but does not 
increase the disease frequency. 
6. Drugs- the following drugs will cause exacerbation of psoriasis- beta 
blockers, lithium, Anti malarial,Imiquimod, Interferons α and γ, ACE 
inhibitors, sodium valproate, carbamazepines, clonidine, glibenclamide 
and tetracyclines. 
7. Smoking and alcohol causes exacerbation. 
8. Obese patients have a severe form of the disease. 
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Clinical features 
Psoriasis presents with a chronic symmetrical erythematous well 
defined dry red scaly papules and plaques with a predilection for the extensor 
aspect of the limbs. 
Clinical classification 
1. Guttate psoriasis- small papules. 
2. Chronic plaque psoriasis or psoriasis vulgaris- this is the commonest 
type seen in 90% patients 
3. Exfoliative psoriasis or erythrodermic psoriasis 
4. Pustular psoriasis 
5. Psoriasis unguis 
6. Mucuous membrane psoriasis 
7. Arthropathis psoriasis 
8. Regional variations- scalp, face, eyes, body flexures, scrotum, napkin 
area, palms and soles. 
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Psoriatic arthritis 
Its an inflammatory arthritis with negative rheumatoid factor. 
Arthritis occurs in 5-10% of psoriasis patients, it rarely precedes the skin 
involvement. 
Presence of HLA B27, -DR3, -A26, -AB38 are associated with joint 
involvement. 
There are 5 pattenrs of psoriatic arthritis. 
Classic psoriatic arthritis	
It occurs in 16% of the patients 
It involves the Distal inter phalangeal joints of toes and fingers. 
In acute stage the involved joint is swollen and tender and there is swelling of 
juxta articular tissue leading to the so called sausage appearance of joints of 
fingers and toes. 
Rheumatoid type  
Occurs in 15% patients 
Symmetrical polyarthritis with proximal inter phalangeal joint involvement 
and negative rheumatoid factor. 
 
40 
 
Arthritis mutilans 
It occurs in 5% of the patients 
There is osteolysis and destruction of bones of the hands and feet resulting in 
telescoping of soft tissue and gross deformities. 
Oligoarticular arthritis 
Most common form of arthritis seen in 70% of patients 
Single or few interphalangeal or metacarpophalangeal joints involved in 
asymmetrical manner. 
Psoriatic spondylitis 
There is an association between psoriasis and Ankylosing spondylitis. Though 
spine involvement is present not all patients will develop a full blown 
Ankylosing spondylitis. 
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Treatment  
There are various treatment modalities available for psoriasis and the type of 
treatment depends on the severity of the disease, location of the lesion and 
associated systemic features. 
Topical treatment 
 Glucocorticoids 
 Vitamin D analogues- calcipotriene, calcitriol 
 Topical retinoids- Tazarotene- teratogenic, contraindicated in 
pregnancy 
 Calcineurin inhibitors- Tacrolimus, pimecrolimus- newer 
modality not FDA  approved. 
PUVA 
Psoralin with UV- A exposure. Psoralin is a photosentizer which activates 
with UV-A and clears the lesions. 
UV-B or narrow band UV-B can also be used. 
Systemic treatment 
Systemic steroids are avoided as they can cause severe pustular psoriasis on 
withdrawal. 
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Methotrexate is most commonly used 7.5to 25mg single weekly dose.  
Mechanism of action: It has two distinct mechanisms of action. 
 In the rapidly dividing cells it acts by inhibiting the dihrdofolate 
reductase enzyme. This enzyme is required for the conversion of 
dihydro folate to tetrahydro folate which is essential for DNA and RNA 
synthesis.  
 In autoimmune diseases it reduces the synthesis of leukotriene B4 in 
neutrophils, decreases the concentration of IL-1β in synovial fluid and 
suppresses cell mediated immunity. 
It can cause hepatotoxicity, nephrotoxicity, acute pneumonitis and is a known 
teratogen. It is secreted in the tears. Ocular toxicities include periorbital 
edema, blepharoconjunctivitis, reduced reflex tear secretion and optic neuritis. 
These adverse effects can be reduced with folate supplementation. 
Ciclosporine – it is a macrolide product of the fungus Beauveria nivea. 
Mechanism of action: It is a calcinueurin inhibitor that eliminates T cell 
receptor signal transduction by acting at the NF- AT nuclear factor activated 
T lymphocytes. This down regulates the IL-2 gene transcription and 
expression of CD4 T lymphocytes. 
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It causes hypertension, nephrotoxicity, paresthesia, fatigue, hypertrichosis and 
gingival hyperplasia. Psoriasis patients treated with cyclosporine appear to be 
at a greater risk of developing primary skin cancers.  
Given in a dose of 2.5-5mg/kg/day PO 
Biologics  
Etarnacept – it is a monoclonal antibody against TNFα  
It is found to be effective in treatment of joint disease but not very effective in 
ocular inflammation. If patients on etarnacept develop uveitis it is advised to 
switch to a different TNFα inhibitor. 
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 Ocular manifestations in psoriasis 
The involvement of eye in this skin disorder is known for many years 
but not very extensively documented. It causes inflammation of various coats 
of the eye and the various ocular inflammatory manifestations may show 
exacerbations along with dermatological exacerbations especially the 
epithelial inflammations. (4)  The exact pathophysiology of the various features 
are not well known but a brief review of the manifestations and their possible 
cause of occurrence is as follows. 
Eye lids  
Eyelid involvement in psoriasis can be in the following forms 
 Direct involvement of the lid with hyperkeratotic plaques, these can 
extend onto the lid margin also. 
 Anterior blepharitis is a common manifestation. It is seen more 
commonly in patients with scalp psoriasis. 
 Increased  incidence of meibomian gland dysfunction has been reported 
in patients with psoriasis accounting for posterior blepharitis and 
evaporative dry eye. (4) 
 Blepharitis can also occur as a result of treatment for psoriasis with 
drugs like retinoids. 
 Long term blepharitis maybe associated with complications like 
trichiasis, ectropion, entropion.  
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 Psoriasis is found to be a cause of madarosis (5). 
 
 
 
The above chart highlights the secondary obstructive decrease in 
Meibobian gland function. 
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Dry eye 
Dry eye is a multifactorial disease of the tear film due to reduced tear 
production or excessive tear evaporation, with potential damage to the ocular 
surface. It is accompanied with symptoms of discomfort and visual 
disturbance.  
Dry eye can be classified as aqueous tear deficiency(ATD) , evaporative tear 
deficiency (ETD) or combined. The characteristic findings for dry eye disease 
diagnostic testing are as follows 
 Test  Findings  
Aqueous tear deficiency 
(ATD) 
Tear break up time <10sec considered 
abnormal 
Ocular surface dye 
staining 
Interpalpepbral corneal 
and bulbar conjunctival 
staining 
Schmiers test 5mm or less with 
anaesthesia is abnormal 
Evaporatimeve tear 
deficiency (ETD)  
Tear break up time <10sec considered 
abnormal 
Ocular surface dye 
staining 
Staining of inferior 
cornea and conjunctiva. 
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Etiological factors for dry eye in psoriasis include the following 
 Systemic inflammatory diseases and Arthritis has been associated with 
increased risk of dry eye. 
 Blepharitis and associated meibobianitis can increase dry eye (6)   This 
type of dry eye is usually due to excess evaporation due to lipid 
deficiency.  
 Chronic inflammation of the conjunctiva causes goblet cell dysfunction 
and may cause a reduction in basal tear secretion. 
 Systemic drugs such as retinoids, PUVA therapy and the 
antimetabolites like methotrexate are associated with worsening. (7)  
Pathophysiology - decreased tear secretion and clearance initiates an 
inflammatory response on the ocular surface mediated by cytokines. This 
theory supports the use of anti-inflammatory for the treatment of severe 
dry eye.  
Mild to moderate dry eye is seen in psoriasis patients. This is not sight 
threatening but causes redness, discomfort and transient blurring of vision. 
Sever dry eye may cause punctate corneal involvement, scarring thinning and 
vascularization, these are sight threatening and must be prevented by early 
recognition of the condition and prompt treatment. 
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Conjunctiva (4) 
 Conjunctival involvement in psoriasis is the commonest ocular finding. 
Reported incidence are as high as 64.5 %. 
 Conjunctivitis can be in the form of allergic conjunctivitis with follicles 
or papillae in the palpebral conjunctiva. Toxic conjunctivitis with 
secondary bacterial or viral infections are also reported.  Though not 
sight threatening conjunctivitis causes redness, irritation and watering.  
 Healing may lead to trichiasis , symblepharon or dry eye. Well 
demarcated yellow red plaques maybe seen in the palpebral 
conjunctiva. (9) 
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 Cornea  
 Corneal involvement by psoriasis is rare.  
 Typical corneal lesion described by Pillat in 1934 consists of 3 distinct 
features- epithelium showing thickening with multiple erosions, 
Bowmans membrane showing infiltration with superficial 
vascularization and deeper stromal opacity.  
 Marginal keratitis can occur though infrequently.  
 Cornea maybe involved due to severe dry eye or 
blepharoconjunctivitis. 
 Manifestations include thinning, scarring and superficial 
vascularization. 
 
Episcleritis  
 It is the inflammation of the episcleral tissue. 
 Episclera is dense vascularised connective tissue between the Sclera 
and the Tenon’s capsule.  
 It has been reported to occur in psoriasis patients (6). Patients present 
with sectoral  or diffuse congestion, discomfort or mild pain. 
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Uvea  
Inflammation of the uveal tract is called uveitis. About 25% of blindness in 
developing countries like India is due to uveitis and its related complications. 
(9) Based on the location of maximum involvement, anatomically it is 
classified by Sun working group as 
Type  Primary site of inflammation  Includes  
Anterior uveitis Anterior chamber Iritis, Iridocyclitis, 
anterior cyclitis 
Intermediate 
uveitis 
Vitreous  Pars planitis, posterior 
cyclitis. Hyalitis 
Posterior uveitis  Retina and choroid Focal, multifocal or 
diffuse choroiditis, 
chorioretinitis, 
retinochoroiditis, retinitis, 
neuroretinitis 
Pan uveitis Anterior chamber, vitreous, 
retina, choroid 
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Uveitis in psoriasis patients presents in the following ways 
 Psoriasis patients have a slight damage to the blood aqueous barrier and 
can present with flare. The severity of flare is associated with the 
disease severity and not the duration of the disease or sex of the 
patient.. (9) 
 Uveitis has traditionally been associated with joint involvement but 
recent studies have shown uveitis to occur independent of joint 
involvement .Iritis in patients with psoriasis without joint involvement 
has characteristic features such as older age of onset approximately 
48yrs, bilateral involvement, longer duration and requires oral 
treatment. Complications like retinal vasculitis, CME, papillitis maybe 
seen. 
 20% patients with psoriasis have joint involvement, 20% of these 
patients develop uveitis. The uveitis is usually acute anterior uveitis 
similar to HLA-B27 associated uveitis but with insidious onset, 
bilateral involvement, chronic course and associated with flare up. 
 There is an association between HLA- B27 and early onset of psoriasis 
and psoriatic arthritis (10). Patients with HLA B-27 have 1-2% lifetime 
risk of developing uveitis, this increases to 7% in patients with psoriatic 
arthritis. 
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 Possible mechanism of uveitis- pathogenesis  
1. Chronic intracellular infection of the joint or eye might stimulate 
an immune response using the MHC class 1 HLA B-27 molecule 
involving a CD8 T lymphocyte effector mechanism activated to 
kill the microbe but indirectly injuring the eye.  i.e individuals 
bearing a specific HLA molecule might be predisposed to 
processing certain antigens such as an infectious agent that cross 
reacts with a self antigen, other individuals lacking this 
haplotype would not be so predisposed. Infectious triggers 
include Chlamydia trachomatis, Klebsiella, Yersinia, Shigella, 
Salmonella, Campylobacter jejuni. 
2. Possible molecular mimicry between HLA molecules and amino 
acid sequence of the antigens. Acute anterior uveitis is a CD4 
Th1 mediated delayed hypersensitivity response. This is seen in 
response to triggers such as 
 Bacteria derived antigens like cell wall antigen or heat 
shock proteins trapped in the uvea 
 Endogenous autoantigens like melanin associated antigens, 
type 1 collagen, myelin associated proteins. 
53 
 
3. The T lymphocyte antigen receptor gene maybe the susceptibility 
factor. 
 Severe sight threatening posterior segment involvement maybe seen in 
psoriasis patients, this is a under recognized phenomenon. (11) (12) 
 Clinical presentation of uveitis 
o Acute anterior uveitis- patients present with pain , photophobia , 
redness. On examination anterior non granulomatous type of 
uveitis with fine KP’s, flare and cells is common. 
o  It maybe associated with intermediate uveitis presenting with 
pars planitis, vitritis, snow ball formation. 
o Rarely posterior involvement with a peripheral chorioretinitis 
occurs. 
o The patients may also have unexplained poor vision with no 
signs of acute inflammation. 
 Due to the varied presentation any patient with defective vision must 
have an ophthalmic evaluation. 
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AIM  
Psoriasis is an autoimmune disease with many extra cutaneous 
manifestations. There is not much data on the ocular manifestations of 
psoriasis in south Indian population. The aim of this study is to analyze the 
various ocular abnormalities in patients with psoriasis.   
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MATERIALS AND METHODS 
This is a cross sectional, descriptive, non interventional hospital based study. 
The period of study was from May 2012 to august 2013. 
Institutional ethical committee approval for conducting the study was 
obtained. 
Patients presenting to the dermatology department of Stanley medical college, 
diagnosed with psoriasis were examined for ocular manifestations at the 
department of ophthalmology, Stanley medical college. Sampling technique 
was consecutive and 75 patients (150 eye) were enrolled in this study. 
Importance of ocular examination was explained to the patients. Evaluation 
procedures were explained and an informed consent was taken from all the 
patients. After obtaining the consent the 150 eye were thoroughly examined. 
The following evaluation was done 
 Relevant ocular history. 
 Duration of psoriasis and the treatment taken. 
  Best corrected visual acuity 
 Slitlamp evaluation of the anterior segment. 
 Posterior segment evaluation with indirect ophthalmoscope and 
slitlamp biomicroscopy using 90D. 
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 IOP measurement using Goldmann applanation tonometry. 
 Dry eye evaluation by 
o Schirmer test using whatmann 41 filter paper. Schirmers 1 
tests both basal and reflex tear secretion. It is done by 
placing the filter paper in an un anaesthetized cornea for 5 
minutes. Wetting less than 10mm after 5 min is considered 
abnormal. 
Schirmers 2  tests the basal secretion it done after applying 
paracaine drops. Wetting less than or equal to 5mm after 5 
min is considered abnormal. 
o Tear break up time- a TBUT of <10 seconds was taken as 
abnormal. 
o Ocular surface staining with fluorescein dye- 
interpalpebral corneal and bulbar conjunctival staining in 
ATD, inferior cornea and bulbar conjunctiva is seen in 
ETD. 
 Fundus pictures and FFA was done when appropriate. 
 X-rays were taken when required. 
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 INCLUSION CRITERIA 
o All psoriasis patients 
 
 Exclusion criteria 
o Patients with other serious comorbid conditions 
o Patients on PUVA therapy 
o Patients with other systemic illness like DM ,HT, 
Bronchial asthma which may have similar ocular findings.  
 
 
 
 
 
 
 
 
 
59 
 
OBSERVATIONS AND DISCUSSION 
In this study, a total of 75 patients  of psoriasis who were referred from 
department of dermatology Stanley medical college to the department of 
ophthalmology were enrolled in the study after obtaining informed consent 
and were subjected to through ocular examination. 
DEMOGRAPHIC DATA 
Age incidence 
The age distribution of the patients included in this study is as follows: 
GRAPH 1: Age distribution 
 
Maximum no. of patients are in the age group of 30-70 yrs. The range 
included patients from 14 yrs to 80 yrs. The mean age group of the patient’s is 
48.24yrs. 
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Sex ratio 
The no. of males in this study were 45, forming 60% of the total no. of 
patients in the study population. The male : female ratio in this study was 3:2. 
Though there is no sex predilection for psoriasis world wide, Indian studies 
show a slight male preponderance. 
TABLE 1: Sex ratio 
Sex No. of cases % 
Males 45 60% 
Females  30 40% 
 
GRAPH 2: Sex ratio 
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Age wise gender distribution 
The age wise male female distribution in the population is almost equal. 
GRAPH 3: Age wise gender distribution: 
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Types of psoriasis in the study population 
The study group consisted of 87% patients of psoriasis vulgaris. 7% had 
Erythrodermic Psoriasis, 4% had Pustular Psoriasis and 2% had Guttate 
Psoriasis. 
TABLE 2: Types of Psoriasis in study population   
Type of psoriasis No. of patients  % 
Psoriasis vulgaris 65 87% 
Erythrodermic psoriasis  5 7% 
Guttate psoriasis 2 2% 
Pustular psoriasis 3 4% 
 
GRAPH 4: Types of Psoriasis in study population   
 
87%
2%
7% 4%
TYPES OF PSORIASIS IN STUDY 
POPULATION
PV GP EP PP
63 
 
Treatment taken by the patients 
The treatment taken by the patients in the study group is as follows: 
TABLE 3: Treatment taken: 
Treatment options no. of patients 
No 18 
methotrexate and etarnacept 50 
methotrexate and etarnacept 4 
Etarnacept 3 
 
GRAPH 5: 
 
Majority of the patients were under treatment for their dermatological 
condition. 67% were prescribed T. Methotrexate. 24% were newly diagnosed 
patients and were not on any treatment at the time presentation.  
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No. Of patients with, scalp involvement, nail involvement and joint 
involvement 
Psoriasis can be plaque type involving any part of the body. The 
occurrence of scalp psoriasis is associated with increased ocular findings in 
many studies. The patients with scalp involvement in our study population 
was 61.33%. Nail involvement was seen in 45.33% patients and joint 
involvement was seen in 12% of the patients. 
TABLE 4: scalp, nail and joint involvement in study population 
Other findings No. of patients  % 
Scalp involvement 46 61.33% 
Nails involvement 34 45.33% 
Scalp and nail 
involvement 
29 38.66% 
Joint involvement 9 12% 
Scalp and joint 
involvement 
6 8% 
Nail and joint 
involvement 
4 5.33% 
Scalp nail and joint 
involvement 
4 5.33% 
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GRAPH 6: scalp, nail and joint involvement in study population 
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Duration of disease among the patients: 
The duration of psoriasis among the various patients is as follows: 
TABLE 5: Disease duration among study population: 
Duration of disease no. of patients 
0- 4 yrs 27 
5-9yrs 17 
10- 14yrs 16 
15-20yrs 14 
> 20yrs 1 
 
GRAPH 7: Disease duration among study population: 
 
 
58.66% of patients are having duration of disease < 10 years. The average 
duration of disease in this study was 6yrs.  
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OCULAR MANIFESTATIONS 
No. Of Patients Who Were Symptomatic 
With regard to ocular complaints among the screened population, 
38.66% were symptomatic whereas 61.33% were asymptomatic.  
TABLE 6: Symptomatic and asymptomatic distribution of patients: 
 NO. OF PTS % 
SYMPTOMATIC 28 37.33% 
ASYMPTOMATIC 47 62.66% 
 
GRAPH 8: Symptomatic and asymptomatic distribution of patients: 
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1. Symptom Profile 
TABLE 7: symptom profile 
Ocular Symptoms No of Pts 
No 47 
Burning Sensation 5 
Redness 12 
Irritation 2 
Defective Vision 7 
Defective Vision + Redness 1 
Defective Vision Pain Photophobia 1 
  
Among the symptomatic patients the most common symptom was redness 
seen in 42.85% pts, followed by defective vision in 25% patients. 7% of the 
symptomatic patients had irritation 3.5% patients had pain photophobia and 
redness associated with defective vision. 
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GRAPH 9: symptom profile 
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Various Ocular Findings Seen In Psoriasis Patients Is As Follows: 
TABLE 8: OCULAR FINDINGS IN PSORIASIS 
Findings  No. of eyes % 
Blepharitis 38 25% 
Conjunctivitis 34 22.66% 
Pterygium 8 5.33% 
Pingicula 12 8% 
Corneal involvement 2 1.3% 
Episcleritis 5 3.33% 
Lens changes 29 19.33% 
Uveitis 5 3.33% 
 
In my study group consisting of 150 eyes the various ocular findings 
observed were Blepharitis seen in 25% followed by Conjunctivitis in 22.66%. 
Corneal involvement in 1.3%. 3.4% of Episcleritis cases were seen.19.33% 
had lens changes. 3% of the patients had Uveitis. 
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GRAPH 10 : OCULAR FINDINGS IN PSORIASIS 
 
Among the study population 25% had Blepharitis. It was seen as 
a direct extension of the plaques onto the lid in 11.33% of the patients. 
It was also seen apart from direct extension in 19.33% of the patients. 
Conjunctival involvement in the form of pterygium and pingicula 
was seen in the study population but there is no increased association of 
occurrence of these conditions in psoriasis patients. 22.66% patients 
had conjunctivitis in our study.  
Corneal involvement was seen in 2 eyes among the study 
population. Both the patients had nebular corneal opacities. No cases of 
keratitis or corneal vascularization were seen in the study population. 
Episcleritis was seen in 5 eyes 3.3% of the population. 
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Lens changes were seen in 29 eyes. These were normal age 
related changes and no increase in the incidence of presenile cataract 
was noted. 
2 patients with uveitis were pseudophakic and other 2 did not have lens 
changes. No other cases of complicated cataract were noted among the 
study population. 
Uveitis was seen in five eyes 3.33% of the population. One 
patient was referred from dermatology with complaints of pain, redness 
photo phobia and defective vision, he had a recurrent bilateral non 
granulomatous type of anterior and intermediate uveitis. This patient 
was not on immunosuppressive at the time of referral. On examination 
patient had circumciliary congestion, fine KP’s on the cornea, flare 4+ 
and cells 3+ in AC, vitreous cells and later membrane formation. Other 
eye also has KP’s flare 2+ and cells 1+  Patient had associated joint 
involvement for which he was referred to a Rheumatologist. Patient 
was started on topical and periocular steroids by us and later started on 
oral methotrexate by the Rheumatologist.   
1 eyes of a patient had old K.P’s and flare 1+ suggestive of 
previous attacks of uveitis. Patient was asymptomatic at the time of 
presentation though he had history of pain and redness previously. 
Patient was on immunosuppressive drugs for his dermatological lesions 
and had no recurrences of uveitis or pain during the study period.   
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Blepharitis with direct involvement of lid 
 
Blepharitis 
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Conjunctivitis 
 
Episcleritis  
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Anterior uveitis with fine KP’s 
 
Intermediate uveitis with membrane formation  
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Macular edema 
 
 
FFA picture of macular edema  
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Two eyes of 2 patients presented with painless defective vision and 
were found to have macular edema and vascular sheathing in inferior 
quadrants in the periphery, probably due to previous uveitis. Macular edema 
was confirmed by FFA. Patients also had flare 1+ but no active cells at the 
time of examination. Patients were given periocular steroids for their macular 
edema. These patients had joint involvement and these patients were also 
started on methotrexate for their skin lesions and they did not have any acute 
episodes of uveitis during the study period. 
Uveitis and joint involvement  
Table 9 Uveitis and joint involvement 
Uveitis and joint involvement  No. of patients 
Uveitis with joint involvement  3 
Only uveitis  1 
 
Among the 5 uveitis patients 4 had joint involvement (75%). 1 male 
patient with active uveitis had acute joint involvement also, sacroiliac joint 
was affected and was started on treatment. 2 female patients had peripheral 
joint involvement and were already on treatment, they had macular edema 
with periphebilits. 1  male patient (25%) had no joint involvement, he had 
chronic uveitis.  
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Graph 11 Uveitis and joint involvement: 
 
 
 
 
Ocular manifestations in asymptomatic patients 
The various manifestations seen among the patients who were 
asymptomatic during the study period are as follows: 
TABLE 10: Ocular manifestations in asymptomatic patients: 
Manifestations  No. of eyes  % 
Blepharitis  23 48% 
Conjunctivitis 13 27.65% 
3
1
uveitis and joint involvement
uveitis with joint involvement only uveitis
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Episcleritis 3 6.38% 
Corneal involvement 1 2.12% 
Uveitis 1 2.12% 
 
GRAPH 12 : Ocular manifestations in asymptomatic patients: 
 
Among the 75patients in the study population, 47 were asymptomatic.  
Among those 47 patients the ocular manifestations observed were 23 eyes 
(48%) had Blepharitis, 13 eyes ( 27.65%) had Conjunctivitis, 3 eyes (6.38%) 
had Episcleritis , 1eye (2.12%) had Corneal involvement and 1eye (2.12%) 
patient with chronic Uveitis was asymptomatic. This highlights the need for 
screening of even the asymptomatic patients as they can also develop sight 
threatening complications. 
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Duration of disease and ocular manifestation  
The association of duration of the disease and ocular manifestations is as 
follows: 
TABLE 11: Duration of disease and ocular manifestations: 
Disease No. of Blepharitis Conjunctivitis Corneal Uveitis 
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duration patients involvement 
< 
10years 
44eyes 33eyes 39 eyes 2 eye 2 eyes 
>10 
years 
31eyes 13 eyes 16 eyes 0 1 eye 
 
Though the distribution of patients among the two groups is unequal 
there was no significant correlation between the duration of the disease and 
ocular inflammation in our study. 
 
 
Scalp involvement and Blepharitis 
The association of scalp involvement in psoriasis and Blepharitis in our study 
is as follows 
TABLE 12: Association of scalp involvement and Blepharitis: 
Scalp involvement No. of patients Blepharitis % 
Yes 46 38 82.66% 
No 29 7 24.13% 
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GRAPH 13: Association of scalp involvement and Blepharitis: 
 
Presence of scalp lesions is associated with occurrence of Blepharitis in 82% 
of patients in our study.24% of the patients without scalp lesions had 
Blepharitis. 
 
OCULAR SURFACE DISORDER IN PSORIASIS PATIENTS  
The ocular surface disorders seen among the study population is as follows: 
TABLE 13: Ocular surface disorder in psoriasis patients: 
Test No. of patients 
Schirmer’s 1  <10mm 30 (20%) 
Schirmer’s 1  >10mm 120 
Schirmer’s 2  <5mm 51(34%) 
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Schirmer’s 2  >5mm 99 
TBUT >10sec 91(60%) 
TBUT <10 sec 59 
 
GRAPH 14: Ocular surface disorder in psoriasis patients: 
 
Scheirmer’s 1 measures the reflex and basal tear secretions it was 
reduced in 30 eyes (20%), schirmer’s 2 measures the basal secretion this was 
reduced in 51 eyes (34%) and 59 (59.8%) eyes had a reduced tear film break 
up time.  These observations indicate that reflex secretion was unaffected but 
the basal secretion was more affected. The tear film instability was also seen 
in these patients, due to increased Meibobian gland dysfunction and 
Blepharitis.   
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DISCUSSION 
Ocular manifestations in psoriasis has been studied by few other 
researcher’s world over. In this study the patients belonged to age group of 
10-80 years (graph1) with a clustering of patients in the average age range of 
48.24 yrs. There was a slight male preponderance in the study but this is 
probably due to more access of male patients to health care services in our 
country (table 1, graph 2).  The age wise distribution of the patients among 
the sexes was equal (graph 3). 
Majority of the patients were having psoriasis vulgaris predominantly 
with joint involvement seen in 12% of the patients (table 3, graph 4).76% of 
these patients were on treatment for their dermatological condition (table 4, 
graph 5).  
The duration of disease in the study population ranged from few 
months to more than 20 years with a mean range of 6 years duration of 
psoriasis (table 5, graph 7). Though the patients were not equally distributed 
with regard to duration of disease the ocular manifestations seen had no 
significant correlation between the duration of the disease and the ocular 
manifestations (table 11). Similar results were noted by Okamoto and 
Umebayasi (1) who noted an association between the increased presence of 
flare in patients with uveitis to be related to the severity of the disease and age 
of onset of disease and no relationship with the duration of disease. 
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Majority of the patients in our study were asymptomatic (table 6, graph 
8). Amongst the asymptomatic patients also ocular manifestations were 
observed which included Blepharitis, Conjunctivitis, Episcleritis, Corneal 
involvement and Uveitis (table 10, graph 12). The presence of this sight 
threatening complication amongst the asymptomatic population was a cause 
of concern and a strong indicator that screening is essential in psoriatic 
patients. 
Blepharitis:	
		
Amongst the symptomatic patients redness was the most common 
symptom and Blepharitis was the most common finding (table 8).  
Study  Blepharitis  
Limba FB et al (3) 12.5% 
Present study  25% 
 
This is similar to other studies which have reported increased incidence 
of both anterior and posterior Blepharitis among the psoriasis patients. (2) The 
incidence of Blepharoconjunctivis in a study by Ibrahim Erbagci et al in the 
Turkish population was 64.5 %. (2) 
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Conjunctival involvement  
Conjunctival involvement in the form of conjunctivitis , pterygium and 
pingicula was seen in our study this is similar to the findings seen in other 
studies. 
Parameter  Limba FB (2) J R Lambert (4) Present study  
Pterygium  5% NA 5.33% 
Pingicula 20% NA 8% 
Conjunctivitis 12.5% 19.6% 22.66% 
 
The occurrence of pterygium and pingicula is not significantly associated with 
psoriasis and there is no increased incidence of its occurrence in psoriasis 
patients. The occurrence of conjunctivitis is associated to psoriasis and the 
incidence is similar to other studies. 
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Corneal manifestations: 
 
Study  Corneal involvement 
Peter Eustace et al (4) Reported 2 cases of psoriatic patients 
with peripheral ulcerative keratitis 
which responded to steroids 
Moadel K et al (5) Reported a case of stromal abscess in 
a patient with psoriasis  
Present study Two patients with old nebular opacity 
no active keratitis. 
 
Corneal involvement have been reported by Peter Eustace and Dermot 
Pierse (3) in the form of stromal involvement and peripheral ulcer with 
vascularisation. Moadel K also reported a case of corneal abscess without 
epithelial involvement in a psoriasis patient which responded well to topical 
steroids. (4) In our study two patients with corneal opacity were observed. No 
cases with active keratitis were seen probably because the patients were 
already on systemic immunosuppressive therapy. 
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Uveitis 
 
Uveitis was seen in five eyes. 1 patient had active uveitis which was 
non granulomatous anterior and intermediate type. This patient had associated 
joint involvement in the form of sacroilitis. This is the classical way in which 
uveitis presents along with psoriasis. Usually it’s an acute anterior uveitis but 
this patient had both anterior and intermediate uveitis. A bilateral, chronic 
uveitis with posterior pole involvement and insidious onset are characteristic 
of uveitis in psoriatic arthritis. HLA DR13, axial skeletal involvement in the 
form of syndesmophytes and bilateral sacroilitis are strong predictors of 
occurrence of uveitis in patients with joint involvement. (5) 
  Another patient with chronic uveitis had psoriasis for 20yrs but no joint 
involvement. Recent studies show that uveitis may occur in psoriasis patients 
even without joint involvement. (6)   
Posterior segment involvement in uveitis is less well recognized than 
the anterior segment involvement. In our study 2 patients had macular edema 
and vascular sheathing. This is similar to other studies which have reported 
occurrence of posterior segment involvement in psoriatic uveitis. (6)   
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Studies  Uveitis  
J R Lambert et al (4)- reported Iritis  7.1% 
Limba FB et al (3)  5% 
Chandra NS et al (8) 2% 
Ruben Queiro et al (7) 18% 
Present study  3.33%  
 
The incidence of uveitis is our study is slightly less compared to other 
studies probably because most of the patient in our study were on 
immunosuppressive treatment for their skin lesions. 
The characteristics of uveitis and joint involvement was reported by 
Eduardo s Paiva et all in the Ann of Rheumatic disease (9) they reported 100% 
of patients with uveitis and axial arthritis to be males. Similarly the patient 
with uveitis in our study had axial involvement and was a male patient. They 
reported bilateral involvement in 37.5 % in our study it was seen in 20 % of 
the patients. They reported chronic duration for 31% of the patients and 
posterior uveitis in 44%. Posterior involvement was seen in 40% in our study 
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Parameter  Eduardo. S Paiva et al (9) Present study 
No. of patients with 
axial involvement and 
uveitis who were males  
100% 100% 
Bilateral involvement  37.5%  20% 
Posterior involvement  44% 40% 
 
In our study there was a strong correlation between the occurrence of 
scalp lesions and Blepharitis seen in 82% patients (table 12, graph 13). 
Dry	eye:	
There is an increased incidence of dry eye in patients with psoriasis. In 
our study there was reduced TBUT and Schirmers level in the patients. 
Similar results were reported by Her Y et al in 2013 (7)  They evaluated dry 
eye, tear film function and ocular surface changes in 30 patients and 
compared to 30 controls and found no significant change in the Schirmers 
values but a reduction in TBUT and alteration in conjunctival cytology with 
reduced goblet cells. Keratoconjunctivitis sicca was also the commonest 
finding reported in a study among the Brazilian patients with psoriatic 
arthritis. (8)   
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Studies  Dry eye  
J R Lambert et al (4) 2.7% 
Lamba FB et al (3) 15-22% 
Chandran NS et al (8) Increased prevalence 
Ibrahim Erbagci et al (2) Increased incidence of TBUT 
reduction. 
Her Y et al (9) TBUT reduction, conjunctival 
cytology- reduced goblet cells 
Present study  Reduced reflex tear secretion and 
TBUT 
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Results  
The total number of patients in this study were 75. The age distribution 
ranged from 14 to 80 yrs with average age being 48.24 yrs. 
 Males formed 60% of the study population with a male to female ratio of 3:2 
87% of the study population consisted of patients with psoriasis vulgaris. 
Scalp involvement was seen in 61.33% of patients, nail involvement in 
45.33% and joint involvement was seen in 12% of the population. 
62.66% of the patients were asymptomatic whereas only 37.33% of the 
patients had some symptoms. The most common symptom was redness 
followed by defective vision, irritation, pain and photophobia. 
There was no association of disease duration and the ocular manifestations. 
Of the 150 eyes most common ocular manifestation was 
Blepharoconjunctivits seen in 25% of the population. Among the patients 
with scalp involvement 82% had Blapharitis also. 
Corneal involvement in the form of old nebular opacities was seen in 1.3% 
patients. 
 Episcleritis was seen in 3.3% of the population. 
 Acute non granulomatous anterior uveitis was seen in 2 eyes. This patient 
had associated joint involvement also. Chronic uveitis was seen in 1 eye of a 
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patient without joint involvement. Defective vision due to macular edema 
probably as a complication of uveitis was seen in 2 eyes of 2 patients. 
Joint involvement associated with uveitis was seen in 75% of the patients and 
25% had uveitis without joint involvement. 
There was increased occurrence of dry eye in these patients as observed by 
reduced Schirmer’s and tear break up time. 
Ocular manifestations were seen even in the asymptomatic patients with 
Blepharoconjunctivitis being the most common finding, seen in 48% of 
asymptomatic patients. One patient with chronic uveitis was asymptomatic 
and the presence of this indicates that routine evaluation of patients is 
essential. 
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CONCLUSION	
Psoriasis is a chronic dermatological disease with extra cutaneous 
involvement of the eye. It can affect almost all structures of the eye from 
anterior to posterior segment, as a part of the disease process. The various 
treatment modalities for the condition may also increase the ocular morbidity.  
The various manifestations include Blepharoconjunctivitis being the 
most common finding followed by Episcleritis and Uveitis. Among these 
uveitis is a potential sight threatening complication and must be detected early 
and treated promptly to prevent irreversible loss of vision. 
The patients are usually asymptomatic as the manifestations are often 
subtle and easily missed. Uveitis may present with defective vision alone and 
no other symptoms of acute uveitis and hence a high degree of suspicion is 
required for early diagnosis and prompt treatment. 
The ocular manifestations have been traditionally associated with joint 
involvement but they may be seen in patients even without joint involvement 
as seen in our study. Hence all patients with psoriasis irrespective of joint 
involvement must be screened for ocular manifestations. 
   The occurrence of Blepharitis was more in patients with scalp 
involvement and so those patients with scalp psoriasis must be evaluated for 
Blepharitis and lid hygiene must be taught. 
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 There is an increased prevalence or dry eye among psoriasis patients. 
The patients must be evaluated to be diagnosed and treated in the early stages 
before severe keratoconjunctivitis occurs to prevent irreversible ocular surface 
changes. 
 Psoriasis affects the skin, joint and eyes. The exact mechanism of this 
is unknown but T cell mediated responses as postulated. Due to multi system 
involvement a combined treatment approach involving screening and early 
treatment of ocular manifestations in psoriasis patients is required to reduce 
the morbidity of the patient and for complete patient care. 
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Abbreviations	used	
B- blepharitis 
CPN- colour pattern normal 
DL- direct involvement of lid. 
E- etarnacept 
EP- erythrodermic psoriasis 
FFA- Fundus Fluorescence 
Angiogram 
GP- Guttate Psoriasis 
HLA- Human Leucocyte antigen 
IMC- immature cataract 
M- methotrexate  
Mand E- methotrexate and 
etarnacept 
MC- mature cataract 
MHC- major histocompatibility 
atigen 
n- no 
N- normal 
ND- normal depth 
NS- Nuclear sclerosis 
PCIOL- posterior chamber Intra 
ocular lens 
PV- Psoriasis Vulgaris 
RAPD- relative afferent pupillary 
defect 
RTL – reacting to light 
Y- yes 
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PROFORMA CASE SHEET 
 
NAME:        AGE:     SEX: 
occupation: 
Presenting complaints: 
  H/o redness 
  H/o pain in the eyes 
  H/o watering 
  H/o irritation 
  H/o defective vision 
  H/o photophobia. 
  H/o discharge 
 
 
Past history: 
Duration of Psoriasis: 
Treatment history: 
Joint, scalp, nail involvement: 
Other systemic diseases: 
 
 
Family history: 
 
Treatment history: 
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Ocular examination: 
            RE        LE 
Vision 
Vision with pin hole 
Retinoscopy 
 
Subjective 
Eyelids 
Eyelashes 
EOM 
 
Conjunctiva  
Cornea  
AC 
Iris  
Pupil 
Lens 
IOP 
Duct: 
SLE: 
 
Fundus: 
Schmiers test 
  l : RE 
      LE 
  ll: RE 
      LE 
TBUT: 
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1 Parmeshwari 42 F PV 5YRS No N N NO M  6/6 6/6 N N N N concrEPISCclear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear c.d 0 c.d 0 17 17 >10 >10 >5 >5 >10 >10
2 Alfred  76 M PV 5YRS No Y Y NO No 6/36 6/36 B B N N N N N N ND ND CPN CPN 3mm RTL 3mm RTL IMC IMC N N 16 16 9 9 4 4 >10 <10
3 Gangadharan 32 M PV 1YRS BurningY N NO No 6/6 6/6 n n N N Pingicpingi N N ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 12 14 >10 >10 >5 >5 >10 >10
4 Sathish 21 M PV 1YRS No Y N NO M 6/6 6/6 DL n n n conjuconjuN N ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 12 12 >10 >10 >5 >5 >10 >10
5 Logu 32 M PV 6MONTHS No N Y NO M 6/6 6/6 N N N N conjuconjuN N ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 14 16 >10 >10 >5 >5 >10 >10
6 Kuppuram 66 M PV 15YRS Rednes Y N NO M 6/24 6/24 N N N N conjuconjuN N ND ND CPN CPN 3mm RTL 3mm RTL IMC IMC N N 18 18 10 10 4 4 >10 <10
7 Arivaraghan 44 M PV 5YRS No Y N NO M 6/6 6/6 N N N N N N N N ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 12 14 >10 >10 >5 >5 >10 >10
8 Selvaraj 63 M PV 1MONTH No N N NO M 6/12 6/12 N N N N N N N N ND ND CPN CPN 3mm RTL 3mm RTL PCIOL PCIOL N N 14 12 >10 >10 >5 >5 >10 >10
9 Ruban 14 M GP 1MONTH No N N NO M 6/6 6/6 N N N N CONCCONCN N ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 14 14 >10 >10 >5 >5 >10 >10
10 Murugsan 58 M PV 15YRS No N N NO M PL‐ 6/18 N N N N N N n OLD KP ND flare  CPN CPN RAPD 3mm RTL IMC IMC OPTI N 10 16 >10 >10 >5 >5 >10 >10
11 Ponnan 36 M PV 10YRS No N N NO M 6/6 6/6 N N N N N N N N ND ND CPN CPN 3mm RTL 3mm RTL clear clear TILTETILT 14 14 >10 >10 >5 >5 >10 >10
12 S.Lakshmanan 42 M PV 3YRS Rednes Y N NO M 6/6 6/6 N N N N conjuconjuN N ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 12 12 >10 >10 >5 >5 >10 >10
13 Radhakrishnan 55 M PV 10YRS IrritatioY N NO M 5/60 6/60 N N N N PTER PTERN N ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 16 16 8 8 3 3 >10 <10
14 Padmavathy 28 F PV 15YRS Rednes Y N NO No 6/6 6/6 B B N N conjuconjuN N ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 12 12 >10 >10 >5 >5 >10 >10
15 Lakshman 45 F PV 15YRS No N Y NO M 6/6 6/6 N N N N N n N N ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 16 16 >10 >10 >5 >5 >10 >10
16 Munusamy 70 M PV 2YRS BurningY Y NO M 6/36 6/60 B B N N N N INFERINFERIOND ND PSEUDPSEUD3mm RTL 3mm RTL NS PCIOL N N 20 14 >10 >10 5 5 >10 <10
17 Raja 37 M PV 6YRS BurningN N NO No 6/6 6/6 N N N N conjuconjuclear CLEAR ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 14 14 8 10 4 5 >10 <10
18 Nazer Ahmed 57 M PV 10YRS Rednes Y Y NO E 6/36 6/36 N N N N N N clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 14 12 >10 >10 >5 >5 >10 >10
19 Habibullah 65 M EP 4YRS IrritatioY Y NO No 6/18 6/18 B B N N N N clear clear ND ND CPN CPN 3mm RTL 3mm RTL IMC IMC N N 16 14 4 5 4 5 >10 <10
20 Padma  54 F PP 20YRS Rednes Y Y NO M An6/12 6/24 N N N N N N clear clear ND ND CPN CPN IRREGULAR3mm RTL PCIOL PCIOL N N 14 14 5 6 4 4 >10 <10
21 Ravi 46 M PV 7YRS No N N NO M 6/9 6/9 B B N N N N NEBUclear ND ND CPN CPN 3mm RTL 3mm RTL clear clear MYE N 14 12 >10 >10 >5 >5 >10 <10
22 Nagapushpam 42 F EP 10YRS Rednes N N NO M 4/60 6/18 N N N N PTER PTER clear clear ND ND CPN CPN 3mm RTL 3mm RTL IMC PCIOL N N 16 16 >10 10 10 2 >10 <10
23 Santharam 60 M PV 6YRS No N N NO M 6/36 6/36 N B N N PTER N clear clear SHALSHAL CPN CPN 3mm RTL 3mm RTL IMC IMC N N 14 16 >10 >10 2 4 >10 <10
24 Samatha 80 F EP 10YRS DefectivY Y NO No PL+ 3/60 B B N N N N clear clear SHALSHAL CPN CPN 3mm RTL 3mm RTL MATU NS NO VNOV 18 18 7 8 4 4 >10 <10
25 Ranganathan 60 M PV 1YRS No Y Y NO No 5/60 6/60 N N N N PTER N clear clear SHALSHAL ATROPATRO 3mm RTL 3mm RTL IMC IMC ARMARM 16 16 >10 9 >5 4 >10 <10
26 Elumalai 58 M PV 18YRS DefectivY Y NO No 6/24 6/24 B B +  N N Pingicpingi clear clear ND ND CPN CPN 3mm RTL 3mm RTL IMC IMC N N 18 18 10 >10 3 >5 >10 >10
27 Lakshmi 55 F PV 6YRS DefectivN N YES M 6/36 6/36 N N N N Pingicpingi clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear MACMAC 14 12 >10 >10 >5 >5 >10 >10
28 Sakera Begum 38 F PV 10YRS No Y N NO M 6/6 6/6 N N N N N N clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 18 16 >10 >10 >5 >5 >10 >10
29 Anand 27 M PV 2YRS Rednes Y Y NO M 6/6 6/6 DL DL N N EPISCEPISCclear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 12 12 >10 >10 >5 >5 >10 >10
30 Ranganathan  57 M EP 6YRS No Y Y YES M 6/36 6/36 DL DL N N N N clear clear SHALSHAL CPN CPN 3mm RTL 3mm RTL IMC IMC N N 20 22 10 10 3 3 >10 <10
31 Murugamal 67 F PV 8YRS Rednes Y Y NO M 6/12 6/12 DL N N N N N clear clear ND ND ATROPATRO 3mm RTL 3mm RTL PCIOL PCIOL N N 14 12 10 >10 4 >5 >10 <10
32 Varalakshmi 30 F PV 8MONTHS DefectivN N YES M 5/60 6/9 N N N N N N clear clear ND ND CPN CPN IRREGULAR3mm RTL clear clear MACN 12 18 >10 >10 4 3 >10 <10
33 Selvam 40 M PV 10YRS No Y N YES M An6/6 6/6 N N N N N N clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 12 16 >10 >10 >5 >5 >10 <10
34 Vikram 28 M PV 4YRS No Y N NO E 6/6 6/6 DL DL N N N EPISCclear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 16 16 >10 >10 4 5 >10 <10
35 Sambantham 63 M PV 15YRS No Y Y NO M 5/60 PL+ N N N N N N clear clear ND ND CPN CPN 3mm RTL 3mm RTL MATU NS NO VNOV 18 18 >10 >10 3 3 >10 <10
36 Daniel 36 M PV 10YRS No Y Y YES M 6/6 6/6 N N N N N N clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 12 12 >10 >10 >5 >5 >10 >10
37 Sahul Ahmed 47 M PV 6‐7YRS DefectivN N NO M An6/24 6/24 N N N N N conjuclear NEBULAND ND CPN CPN 3mm RTL 3mm RTL IMC clear N N 14 14 >10 >10 >5 >5 >10 >10
38 Laurance 31 M PV 3YRS No Y N YES No 6/6 6/6 N B N CRUN conjuclear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 14 14 >10 >10 >5 >5 >10 >10
39 Muniyammal 47 F PV 35YRS DefectivN N NO M 6/60 6/60 N N N N N N clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear IMC N N 18 18 >10 >10 4 5 >10 <10
40 Chitra 51 F PV 17YRS No Y Y YES M 2/60 2/60 N N N N N N clear clear ND IRREGCPN IRIS CO3mm RTL COLOBOMclear PCIOL N COM 16 12 >10 >10 5 5 >10 <10
41 Mani 44 M PV 12YRS No Y Y YES M 6/9 6/9 N N N N N N clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 14 12 >10 >10 >5 >5 >10 >10
42 Venkatesan 52 M PV 10YRS No Y Y NO No 6/36 6/36 N DL N N N N clear clear ND ND CPN CPN 3mm RTL 3mm RTL IMC IMC N N 12 12 >10 >10 4 5 >10 <10
43 Ranganathan 57 M PV 3MONTHS DefectivN N YES M 6/24 2/60 n n n n n ccc kps kps flare flare  CPN CPN 3mm RTL 2mmrtl PCIOL PCIOL N N 15 18 >10 >10 >5 >5 >10 <10
44 Hemanth 76 M PV 5YRS No N N NO M  6/6 6/6 DL DL n n conjuconjuclear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 16 16 >10 >10 >5 >5 >10 >10
45 Banu 32 F PV 5YRS No Y N NO No 6/6 6/6 DL DL n n conjuconjuclear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 12 14 >10 >10 >5 >5 >10 >10
46 Anitha 21 F GP 1YRS No Y Y NO No 6/6 6/6 n n n n n n clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 12 12 >10 >10 >5 >5 >10 >10
47 Niveda 32 F PV 1YRS No Y Y NO M 6/6 6/6 n n n n n n clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 14 16 >10 >10 >5 >5 >10 >10
48 Kajal 66 F EP 6MONTHS BurningN N NO M 6/6 6/6 n n n n n n clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 18 18 9 8 4 5 >10 <10
49 Banzer 44 F PV 15YRS No Y Y NO M 6/6 6/6 B B n n conjuconjuclear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 12 14 >10 >10 >5 >5 >10 >10
50 Venugopal 63 M PV 5YRS No Y Y NO M 6/6 6/6 n n n n n n clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 14 12 >10 >10 >5 >5 >10 >10
51 Chandrshekar 24 M PV 1MONTH No N Y NO M 6/6 6/6 n n n n n n clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 14 14 >10 >10 >5 >5 >10 >10
52 Imran 58 M PV 1MONTH No N N NO M 6/6 6/6 B B n n conjuconjuclear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 10 16 >10 >10 >5 >5 >10 >10
53 Azad 36 M PV 15YRS No N N NO M 6/6 6/6 n n n n n n clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 14 14 >10 >10 >5 >5 >10 >10
54 Fathima Bee 42 F PV 10YRS No N N NO M 6/6 6/6 n n n n n n clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 12 12 9 9 3 3 >10 <10
55 Kartar Bee 55 F PV 3YRS No Y Y NO M 6/6 6/6 n n n n n n clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 16 16 10 10 5 4 >10 <10
56 Machagandhi 28 F PP 10YRS Rednes Y Y NO M 6/6 6/6 DL DL n n conjuconjuclear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 12 12 >10 >10 >5 >5 >10 >10
57 Zareena 45 F PV 15YRS No Y Y NO No 6/6 6/6 n n n n n n clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 16 16 >10 >10 >5 >5 >10 >10
58 Rahamdh Bee 70 F PV 15YRS No N N NO M 6/6 6/6 n n n n n n clear clear ND ND CPN CPN 3mm RTL 3mm RTL imc imc N N 20 14 >10 >10 >5 >5 >10 >10
59 Sharafath 37 M PV 2YRS No Y N NO M 6/9 6/9 n DL n n conjuconjuclear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 14 14 >10 >10 >5 >5 >10 >10
60 Hakim  57 M PV 6YRS No N Y NO No 6/6 6/6 n n n n n n clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 14 12 >10 >10 >5 >5 >10 >10
61 Tamilarasi 65 F PV 10YRS No Y Y NO E 6/6 6/6 n n n n n n clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 16 14 >10 >10 >5 >5 >10 >10
62 Jayesh 54 M PV 4YRS Rednes Y Y NO No 6/6 6/6 B B n n conjuconjuclear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 14 14 >10 >10 5 2 >10 <10
63 Adil Hassan 46 M PV 20YRS No Y N NO M An6/6 6/6 n n n n n n clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 14 12 >10 >10 >5 >5 >10 >10
64 Madan 42 M PP 7YRS No N N NO M 6/6 6/6 n n n n n n clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 16 16 >10 >10 >5 >5 >10 >10
65 Gopi 60 M PV 10YRS No N N NO M 6/6 6/6 n n n n n n clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 14 16 >10 >10 >5 >5 >10 >10
66 Nazeera Begum 80 F PV 6YRS DefectivN Y NO M pl+ 6/18 n n n n n n clear clear ND ND CPN CPN 3mm RTL IRREGULA MATU pciol NO VN 18 18 >10 >10 >5 >5 >10 >10
67 Geni Das 60 F PV 10YRS Rednes Y Y NO No 6/6 6/6 B B n n conjuCONJclear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 16 16 >10 >10 >5 >5 >10 >10
68 Dayanithy 58 M PV 1YRS No Y N NO No 6/6 6/6 B B n n conjuconjuclear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 18 18 >10 >10 >5 >5 >10 >10
69 Yasmin 55 F PV 18YRS No Y N NO No 6/12 6/12 n n n n n n clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 14 12 >10 >10 >5 >5 >10 >10
70 Jammaludin 38 M PV 6YRS No N N NO M 6/6 6/6 n n n n n n clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 18 16 >10 >10 4 4 >10 <10
71 Jency 27 F PV 10YRS No Y Y NO M 6/6 6/6 n n n n n n clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 12 12 9 7 5 3 >10 <10
72 Santhana Kumar 57 M PV 2YRS DefectivY Y NO M 6/24 6/24 B B n n conjuconjuclear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 20 22 >10 >10 >5 >5 >10 >10
73 Deepa 67 F PV 6MONTHS BurningY Y NO M 6/6 6/6 n n n n n n clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 14 14 10 10 5 5 >10 <10
74 Loganayagi 30 F PV 2YRS Rednes Y N NO M 6/6 6/6 DL B n n n n clear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 12 12 >10 >10 >5 >5 >10 >10
75 Bhanabhagyam 40 F PV 1YRS No N N NO M 6/6 6/6 n n n n n EPISCclear clear ND ND CPN CPN 3mm RTL 3mm RTL clear clear N N 16 16 >10 >10 >5 >5 >10 >10
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HETEROPHORIA BE uveitis
A STUDY OF OCULAR MANIFESTATIONS IN PSORIASIS PATIENTS  
INTRODUCTION 
Psoriasis is associated with several extracutaneous manifestations of which 
ocular complications are common. It may be associated with many 
manifestations such as blepharitis, conjunctivitis, dry eye, episcleritis, scleritis 
and uveitis. Of these uveitis is a serious and sight threatening complication.  
Psoriasis may affect the eye due to direct involvement by the disease or by 
immune mediated mechanisms. The treatment modalities such as retinoids and 
puva can also affect the eye. 
Signs and symptoms of ocular psoriasis may be subtle and overlooked but a 
thorough understanding of ophthalmic involvement is important to the 
comprehensive care of patients with psoriasis.AIM :The aim of this study is to 
determine the prevalence of ocular abnormalities in psoriasis patients and to 
correlate them with the underlying duration of disease.MATERIALS AND 
METHODS:75 psoriasis patients attending Dermatology OPD in Stanley 
medical college hospital from May2012-Aug2013 were included in this 
study.All patients were explained about the purpose of the study and an 
informed consent was taken.Examination included 
 Relevant ocular history. 
 Duration of psoriasis and the treatment. 
 Uncorrected and best corrected visual acuity 
 Slitlamp evaluation of the anterior segment. 
 Fundus evaluation of the posterior segment. 
 IOP measurement using applanation tonometry. 
 Schmeirs test and TBUT test. 
 Systemic examination 
INCLUSION CRITERIA:All psoriasis patients. Exclusion criteria:Patients with 
other serious comorbid conditions.Patients on PUVA therapy.Patients with 
other systemic illness like DM ,HT, Bronchial asthma which may have similar 
ocular findings.  
Results  
The total number of patients in this study were 75. The age distribution ranged 
from 14 to 80 yrs with average age being 48.24 yrs. 
 Males formed 60% of the study population with a male to female ratio of 3:2 
87% of the study population consisted of patients with psoriasis vulgaris. Scalp 
involvement was seen in 61.33% of patients, nail involvement in 45.33% and 
joint involvement was seen in 12% of the population. 
62.66% of the patients were asymptomatic whereas only 37.33% of the patients 
had some symptoms. The most common symptom was redness followed by 
defective vision, irritation, pain and photophobia. 
There was no association of disease duration and the ocular manifestations. 
Of the 150 eyes most common ocular manifestation was Blepharoconjunctivits 
seen in 25% of the population. Among the patients with scalp involvement 82% 
had Blapharitis also. 
Corneal involvement in the form of old nebular opacities was seen in 1.3% 
patients. 
 Episcleritis was seen in 3.3% of the population. 
 Acute non granulomatous anterior uveitis was seen in 2 eyes. This patient had 
associated joint involvement also. Chronic uveitis was seen in 1 eye of a patient 
without joint involvement. Defective vision due to macular edema probably as a 
complication of uveitis was seen in 2 eyes of 2 patients. 
Joint involvement associated with uveitis was seen in 75% of the patients and 
25% had uveitis without joint involvement. 
There was increased occurrence of dry eye in these patients as observed by 
reduced Schirmer’s and tear break up time. 
Ocular manifestations were seen even in the asymptomatic patients with 
Blepharoconjunctivitis being the most common finding, seen in 48% of 
asymptomatic patients. One patient with chronic uveitis was asymptomatic and 
the presence of this indicates that routine evaluation of patients is essential. 
CONCLUSION 
Psoriasis is a chronic dermatological disease with extra cutaneous 
involvement of the eye. It can affect almost all structures of the eye from anterior 
to posterior segment, as a part of the disease process. The various treatment 
modalities for the condition may also increase the ocular morbidity.  
The various manifestations include Blepharoconjunctivitis being the most 
common finding followed by Episcleritis and Uveitis. Among these uveitis is a 
potential sight threatening complication and must be detected early and treated 
promptly to prevent irreversible loss of vision. 
The patients are usually asymptomatic as the manifestations are often 
subtle and easily missed. Uveitis may present with defective vision alone and no 
other symptoms of acute uveitis and hence a high degree of suspicion is required 
for early diagnosis and prompt treatment. 
The ocular manifestations have been traditionally associated with joint 
involvement but they may be seen in patients even without joint involvement as 
seen in our study. Hence all patients with psoriasis irrespective of joint 
involvement must be screened for ocular manifestations. 
   The occurrence of Blepharitis was more in patients with scalp involvement 
and so those patients with scalp psoriasis must be evaluated for Blepharitis and 
lid hygiene must be taught. 
 There is an increased prevalence or dry eye among psoriasis patients. The 
patients must be evaluated to be diagnosed and treated in the early stages before 
severe keratoconjunctivitis occurs to prevent irreversible ocular surface changes. 
 Psoriasis affects the skin, joint and eyes. The exact mechanism of this is 
unknown but T cell mediated responses as postulated. Due to multi system 
involvement a combined treatment approach involving screening and early 
treatment of ocular manifestations in psoriasis patients is required to reduce the 
morbidity of the patient and for complete patient care. 
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